Drug intelligence / Profile preview

Teslanbai

Development stage: Unknown
Lead developer: The First Affiliated Hospital of Xinxiang Medical College
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**Teslanbai** is an orally administered, nano-selenium-enriched *Lactobacillus rhamnosus* probiotic product derived from strain CICC 6137. It is being clinically evaluated for radiation proctitis, where pelvic radiotherapy-associated intestinal dysbiosis, oxidative stress, epithelial injury, inflammation, and impaired intestinal-barrier function contribute to disease. The product is intended to modulate the gut microbiota and reduce oxidative stress through selenium-associated antioxidant activity, thereby supporting mucosal-barrier repair and reducing intestinal inflammation. A Phase I/II study sponsored by The First Affiliated Hospital of Xinxiang Medical College is evaluating oral Teslanbai in patients with radiation proctitis.

Other names: Teslanbai bacteriaTeslanbaicin

Beyond the preview

Go deeper on Teslanbai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teslanbai.

Explore the full profile